The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2

International Journal of Infectious Diseases

Volumn 14, Issue 7, 2010, Pages

  Chemaly, R F ^a   Sharma, P S ^a   Youssef, S ^a   Gerber, D ^a   Hwu, P ^a   Hanmod, S S ^a   Jiang, Y ^a   Hachem, R Y ^a   Raad, I I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Blood stream infection; Catheter related bacteremia; IL 2 therapy; Melanoma; Renal cell carcinoma

Indexed keywords

INTERLEUKIN 2; MINOCYCLINE; NAFCILLIN; RIFAMPICIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CANCER PATIENT; CANDIDEMIA; CATHETER INFECTION; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; REVIEW; CENTRAL VENOUS CATHETERIZATION; COMPLICATION; INDWELLING CATHETER; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTEREMIA; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; FEMALE; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; MINOCYCLINE; NEOPLASMS; RIFAMPIN; TREATMENT OUTCOME;

EID: 77953293518     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.08.007     Document Type: Review

References (39)

1. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271 (2004) 907-913
2. Atkins M.B., Lotze M.T., Dutcher J.P., Fisher R.I., Weiss G., Margolin K., et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 (1999) 2105-2116
3. Atkins M.B., Kunkel L., Sznol M., and Rosenberg S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6 (2000) S11-S14
4. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C., et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 (1995) 688-696
5. Fisher R.I., Rosenberg S.A., and Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6 (2000) S55-S57
6. Rosenberg S.A., Yang J.C., White D.E., and Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 (1998) 307-319
7. Belldegrun A., Webb D.E., Austin III H.A., Steinberg S.M., Linehan W.M., and Rosenberg S.A. Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. J Urol 141 (1989) 499-503
8. Margolin K.A., Rayner A.A., Hawkins M.J., Atkins M.B., Dutcher J.P., Fisher R.I., et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7 (1989) 486-498
9. Margolin K., Jaffe H.S., and Hawkins M. Toxicity of interleukin-2 and lymphokine-active killer cell therapy. Proc Am Soc Clin Oncol 6 (1987) 251
10. Guleria A.S., Yang J.C., Topalian S.L., Weber D.R., Parkinson D.R., MacFarlane M.P., et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 12 (1994) 2714-2722
11. Klempner M.S., Noring R., Mier J.W., and Atkins M.B. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322 (1990) 959-965
12. Snydman D.R., Sullivan B., Gill M., Gould J.A., Parkinson D.R., and Atkins M.B. Nosocomial sepsis associated with interleukin-2. Ann Intern Med 112 (1990) 102-107
13. Pockaj B.A., Topalian S.L., Steinberg S.M., White D.E., and Rosenburg S.A. Infectious complications associated with interleukin-2 administration: a retrospective review of 935 treatment courses. J Clin Oncol 11 (1993) 136-147
14. Richards J.M., Gilewski T.A., and Vogelzang N.J. Association of interleukin-2 therapy with staphylococcal bacteremia. Cancer 67 (1991) 1570-1575
15. Lim S.H., Giles F.J., Smith M.P., and Goldstone A.H. Bacterial infection in lymphoma patients treated with recombinant interleukin-2. Acta Haematol 85 (1991) 135-138
16. Bock S.N., Lee R.E., Fisher B., Rubin J.T., Schwartzentruber D.J., Wei J.P., et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8 (1990) 161-169
17. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298 (2007) 1763-1771
18. O'Grady N., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 23 (2002) 759-769
19. Mermel L.A., Farr B.M., Sherertz R.J., Raad I.I., O'Grady N., Harris J.S., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 32 (2001) 1249-1272
20. Chatzinikolaou I., Hanna H., Darouiche R., Samonis G., Tarrand J., and Raad I. Prospective study of the value of quantitative culture of organisms from blood collected through central venous catheters in differentiating between contamination and bloodstream infection. J Clin Microbiol 44 (2006) 1834-1835
21. Raad I.I., Hachem R.Y., Abi-Said D., Rolston K.V.I., Whimbey E., Buzaid A.C., et al. A prospective crossover randomized trial of novobiocin and rifampin prophylaxis for the prevention of intravascular catheter infections in cancer patients treated with interleukin-2. Cancer 82 (1998) 403-411
22. Mier J.W., Vachino G., van der Meer J.W., Numerof R.P., Adams S., Cannon J.G., et al. Induction of circulating tumor necrosis factor (TNF-alpha) as the mechanism for febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8 (1988) 426-436
23. Atkinson Y.H., Marasco W.A., Lopez A.F., and Vadas M.A. Recombinant tumor necrosis factor-alpha: regulation of N-formylmethionylleucylphenylalanine receptor affinity and function on human neutrophils. J Clin Invest 82 (1988) 759-765
24. Tacconelli E., De Angelis G., Cataldo M.A., Pozzi E., and Cauda R. Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. J Antimicrob Chemother 61 (2008) 26-38
25. Raad I., Darouiche R., Dupuis J., Abisaid D., Gabrielli A., Hachem R., et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. Ann Intern Med 127 (1997) 267-274
26. Darouiche R.O., Raad I.I., Heard S.O., Thornby J.I., Wenker O.C., Gabrielli A., et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 340 (1999) 1-8
27. Hanna H.A., Raad I.I., Hackett B., Wallace S.K., Price K.J., Coyle D.E., et al. Antibiotic-impregnated catheters associated with significant decrease in nosocomial and multidrug-resistant bacteremias in critically ill patients. Chest 124 (2003) 1030-1038
28. Chatzinikolaou I., Hanna H., Graviss L., Chaiban G., Perego C., Arbuckle R., et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol 24 (2003) 961-963
29. Hanna H., Benjamin R., Chatzinikolaou I., Alakech B., Richardson D., Mansfield P., et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 22 (2004) 3163-3171
30. Darouiche R.O., Berger D.H., Khardori N., Robertson C.S., Wall M.J., Metzler M.H., et al. Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters. A randomized controlled trial. Ann Surg 242 (2005) 193-200
31. Falagas M.E., Fragoulis K., Bliziotis I.A., and Chatzinikolaou I. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 59 (2007) 359-369
32. Raad I., Darouiche R., Hachem R., Mansouri M., and Bodey G.P. The broad-spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 173 (1996) 418-424
33. Hanna H., Bahna P., Reitzel R., Dvorak T., Chaiban G., Hachem R., et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Chemother 50 (2006) 3283-3288
34. Aslam S., and Darouiche R.O. Prolonged bacterial exposure to minocycline/rifampicin-impregnated vascular catheters does not affect antimicrobial activity of catheters. J Antimicrob Chemother 60 (2007) 148-151
35. Munson E.L., Heard S.O., and Doern G.V. In vitro exposure of bacteria to antimicrobial impregnated-central venous catheters does not directly lead to the emergence of antimicrobial resistance. Chest 126 (2004) 1628-1635
36. Marciante K.D., Veenstra D.L., Lipsky B.A., and Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control 31 (2003) 1-8
37. Shorr A.F., Humphreys C.W., and Helman D.L. New choices for central venous catheters. Potential financial implications. Chest 124 (2003) 275-284
38. León C., Ruiz-Santana S., Rello J., Torre M., Valles J., Alvarez-Lerma F., et al. Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med 30 (2004) 1891-1899
39. Mitsuyasu R., Gelman R., Cherng D.W., Landay A., Fahey J., Reichman R., et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with a moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial - AIDS Clinical trials Group 328. Arch Intern Med 167 (2007) 597-605